医学
四分位数
化疗
淋巴细胞白血病
回顾性队列研究
中性粒细胞减少症
毒性
急性淋巴细胞白血病
儿科
内科学
白血病
置信区间
作者
A E J Yeoh,Anna Collins,Kahlia Fox,Sarah Shields,Petra Ritchie,Maria Kirby,Tamás Révész
标识
DOI:10.1080/08880018.2016.1276235
摘要
Delays or interruptions in chemotherapy due to toxicity such as neutropenia or severe infections are common in the treatment of pediatric acute lymphoblastic leukemia (ALL). Based on the reports of worse outcomes in children with poorer compliance with therapy, there has been concern that toxicity-induced therapy interruptions could also compromise treatment outcome. In a retrospective study of treatment delays in our hospital between 2003 and 2013, the case notes of 141 patients were reviewed. The cumulative lengths of delays during the whole length of chemotherapy, during the intensive phase of treatment, and during maintenance treatment were analyzed. Within these categories, delays were split between less and more than the median value. The risk of relapse did not differ between patients with a longer or shorter delay during the total length of treatment or during the intensive phase. In addition, there was a trend when comparing patients above vs below the mean in length of treatment delays during maintenance, and there was a statistically significant difference in relapses when comparing patients in the lowest and highest quartiles of maintenance delays, with fewer relapses among those patients in the highest quartile for treatment delays.
科研通智能强力驱动
Strongly Powered by AbleSci AI